Nonpartisan civic infrastructure
AllCiv·Legis1
·

H.R. 2831

BillFederalHouseIn Committee
Prompt Approval of Safe Generic Drugs Act
About This Bill
Committee
Latest Action · April 27, 2021
Referred to the Subcommittee on Health.
Congress
117th (2021–2023)
Introduced
April 26, 2021
Cosponsors (0)
None
View PDF ↗

Summary

Highlight any text to annotate
Prompt Approval of Safe Generic Drugs Act This bill authorizes the Food and Drug Administration (FDA) to approve certain applications to market a drug even if the drug's labeling lacks certain safety information. Specifically, an abbreviated application for approval of a generic drug shall not be ineligible for approval solely because the drug's labeling omits safety information that is protected under another drug's exclusivity protections. Similarly, a drug that is approved under this bill shall not be considered mislabeled for lacking such safety information. Generally, an abbreviated application, for the purposes of this bill, is one that (1) uses required information from studies not conducted by the applicant; or (2) seeks approval of a drug that is, for drug approval purposes, a duplicate of an already-approved drug. For any drug approved under this bill, the FDA shall require the drug's labeling to include any safety information that is necessary to assure safe use.

Take Action

Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.